Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 29Recruiting 8Withdrawn 3Unknown 3Terminated 2Not yet recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Clinical Stage III Cutaneous Melanoma AJCC v8 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Absorptiometry, Photon × Clear all
NCT04516122 2025-08-17

Bone Loss in Melanoma Survivors Receiving Immunotherapy

M.D. Anderson Cancer Center

Terminated
12 enrolled
Dermatologic

Clinical Stage III Cutaneous Melanoma AJCC v8

NCT00634582 2018-07-06

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Wake Forest University Health Sciences

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡